

University of Groningen

New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia

van der Helm, Lidia Henrieke

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van der Helm, L. H. (2016). *New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia: Hypomethylating agents and proteasome inhibitors*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia

Hypomethylating agents and proteasome inhibitors

Lieke van der Helm

New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia.
Hypomethylating agents and proteasome inhibitors.

Copyright © 2016 Lieke van der Helm, Groningen, the Netherlands.

All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means without permission from the author or, when appropriate, from the publisher of the publications.

ISBN	978-90-367-9083-3
	978-90-367-9082-6 (PDF)
Author	Lieke van der Helm
Cover design	Suzanne Jansen
Layout	Lieke van der Helm
Printed by	Ipskamp Drukkers BV, Enschede

Financial support for the printing of this thesis is gratefully acknowledged and was provided by Stichting tot bevordering der haematologie Groningen, University of Groningen (RUG), Celgene BV, Greiner Bio-One BV, and BD Biosciences BV.



rijksuniversiteit
 groningen

New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia

Hypomethylating agents and proteasome inhibitors

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. E. Sterken
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 5 oktober 2016 om 16.15 uur

door

Lidia Henrieke van der Helm

geboren op 1 mei 1989
te Apeldoorn

Promotores

Prof. dr. G.A. Huls

Prof. dr. E. Vellenga

Prof. dr. J.J. Schuringa

Beoordelingscommissie

Prof. dr. J.A. Gietema

Prof. dr. A.A. van de Loosdrecht

Prof. dr. M. Lübbert

Paranimfen

Suzanne Jansen

Marinke van der Helm

Contents

Chapter 1	General introduction and scope of this thesis	9
Chapter 2	Platelet doubling after the first azacitidine cycle is a promising predictor for response in MDS, CMML and AML patients in the Dutch azacitidine compassionate patient named program <i>British Journal of Haematology 2011; 155: 599-606</i>	33
Chapter 3	Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts <i>Leukemia research 2013; 37: 877-882</i>	49
Chapter 4	Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single center retrospective study of 227 consecutive patients <i>Journal of Hematology & Oncology 2013; 6: 29</i>	63
Chapter 5A	Long-term outcome in older AML patients treated with hypomethylating agents compared to conventional chemotherapy	83
Chapter 5B	Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukemia. <i>British Journal of Haematology, in press</i>	91
Chapter 6	Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib <i>British Journal of Haematology 2015; 171: 652-655</i>	99
Chapter 7	Summary, discussion and future perspectives	121
Chapter 8	Nederlandse samenvatting	145
Appendix	List of abbreviations	151
	Dankwoord/Acknowledgements	155
	List of publications and Curriculum vitae	161

